1 |
Kawashima S, Matsui Y, Adachi T, Morikawa Y, Inoue K, Takebayashi S, Nobori H, Rokushima M, Tachibana Y, Kato T. Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally. Biochem Biophys Res Commun 2023;645:132-6. [PMID: 36689809 DOI: 10.1016/j.bbrc.2023.01.040] [Reference Citation Analysis]
|
2 |
Islam MA, Shahi S, Marzan AA, Amin MR, Hasan MN, Hoque MN, Ghosh A, Barua A, Khan A, Dhama K, Chakraborty C, Bhattacharya P, Wei DQ. Variant-specific deleterious mutations in the SARS-CoV-2 genome reveal immune responses and potentials for prophylactic vaccine development. Front Pharmacol 2023;14:1090717. [PMID: 36825152 DOI: 10.3389/fphar.2023.1090717] [Reference Citation Analysis]
|
3 |
Zhou Q, Chen Y, Wang R, Jia F, He F, Yuan F. Advances of CRISPR-Cas13 system in COVID-19 diagnosis and treatment. Genes Dis 2022. [PMID: 36591005 DOI: 10.1016/j.gendis.2022.11.016] [Reference Citation Analysis]
|
4 |
Chakraborty C, Bhattacharya M, Dhama K. Cases of BA.2.75 and recent BA.2.75.2 subvariant of Omicron are increasing in India: Is it alarming at the global level? Annals of Medicine and Surgery 2022. [DOI: 10.1016/j.amsu.2022.104963] [Reference Citation Analysis]
|